EUVIMEDObjevte EUVIMED
Crossref

Nirsevimab for Prevention of RSV Infections for Immunocompromised Children With Cancer and Stem Cell Transplant Recipients: A Single‐Center Experience

Adam P Yan iD, Yuqing Feng, Dima El Hassanieh, Allison Starr, Martin Yi, Tal Schechter-Finkelstein, Jennifer Drynan, Lillian Sung iD, Sumit Gupta iD

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.32032 ↗

At a glance

Journal article in Pediatric Blood & Cancer, 2025. Written by Adam P Yan and 8 co-authors. Institution: Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada. Major MEDLINE topics: Respiratory Syncytial Virus Infections, Antibodies, Monoclonal, Humanized, Immunocompromised Host, Neoplasms. 23 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Children with cancer and hematopoietic stem cell transplant (HSCT) recipients are at high risk for severe respiratory syncytial virus (RSV) infections. Nirsevimab, a long‐acting monoclonal antibody approved in 2023, offers single‐dose seasonal protection. We conducted a single‐center study to assess uptake, factors associated with receipt, and RSV outcomes among eligible patients during the 2024–2025 season. Of 42 eligible patients, 62% received nirsevimab. Delays and missed opportunities for administration were common. RSV occurred in both recipients and non‐recipients, including one RSV‐related death in an unvaccinated patient. Clinic type and healthcare contact influenced uptake. These findings highlight the need for improved implementation strategies to optimize RSV prophylaxis in immunocompromised pediatric populations.

Subjects

MeSH terms (MEDLINE)

Respiratory Syncytial Virus InfectionsAntibodies, Monoclonal, HumanizedImmunocompromised HostNeoplasmsHematopoietic Stem Cell TransplantationAntiviral AgentsHumansMaleFemaleChildChild, PreschoolInfantAdolescentFollow-Up StudiesPrognosisRespiratory Syncytial Virus, Human

Author keywords

RSVcancernirsevimabpediatrics

Substances

Antibodies, Monoclonal, HumanizedAntiviral Agents

Authors and institutions

  • Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Program in Child Health Evaluative Sciences, The Hospital for Sick Children, Peter Gilgan Centre for Research and Learning, Toronto, Ontario, Canada.

ORCID profiles: Adam P Yan, Lillian Sung, Sumit Gupta

Cite

APA

Yan, A. P., Feng, Y., Hassanieh, D. E., Starr, A., Yi, M., Schechter-Finkelstein, T., Drynan, J., Sung, L., & Gupta, S. (2025). Nirsevimab for Prevention of RSV Infections for Immunocompromised Children With Cancer and Stem Cell Transplant Recipients: A Single‐Center Experience. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.32032

Vancouver

Yan AP, Feng Y, Hassanieh DE, Starr A, Yi M, Schechter-Finkelstein T, et al. Nirsevimab for Prevention of RSV Infections for Immunocompromised Children With Cancer and Stem Cell Transplant Recipients: A Single‐Center Experience. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.32032

BibTeX
@article{Yan2025,
  author = {Yan, Adam P and Feng, Yuqing and Hassanieh, Dima El and Starr, Allison and Yi, Martin and Schechter-Finkelstein, Tal and Drynan, Jennifer and Sung, Lillian and Gupta, Sumit},
  title = {Nirsevimab for Prevention of RSV Infections for Immunocompromised Children With Cancer and Stem Cell Transplant Recipients: A Single‐Center Experience},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.32032}
}
Start for free →